Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chemotherapy Effect
- KRAS Gene Mutation
- NSCLC Stage IV
- PD-1 Antibody
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03777124
- Collaborators
- Shanghai Chest Hospital
- Investigators
- Study Director: Jianjun Zou, MD, PhD Jiangsu HengRui Medicine Co., Ltd. Principal Investigator: Shun Lu, MD, PhD Jiaotong University,Shanghai chest Hospital
Get Well Soon